Drug-Drug Interactions in Pharmaceutical Development (Wiley Series in Drug Discovery and Development) - Hardcover

Über die Autorin bzw. den Autor

Albert P. Li is the President and CEO of In Vitro ADMET Laboratories, LLC (www.invitroadmet.com), and Advanced Pharmaceutical Sciences, Inc. (www.apsciences.com), and the cofounder, Chairman, and CSO of the ADMET Group (www.admetgroup.com). Dr. Li has over twenty-five years in the drug development industry, is a distinguished international speaker in the field, and has over 150 publications. He has edited several books.

Von der hinteren Coverseite

Early evaluation of potential drug–drug interactions

Addressing the potential for adverse interactions among coadministered drugs before marketing a new drug can save time, money, and lives. In this reference, distinguished international experts comprehensively review the issues, relevant science, industrial practice, and regulatory agency positions on drug–drug interactions. Focusing on evaluation during the drug discovery process, Drug–Drug Interactions in Pharmaceutical Development:

• Details the major scientific concepts and preclinical experimental approaches

• Covers both clinical and nonclinical aspects

• Discusses in vitro and in vivo methodologies

• Covers genomic approaches

• Addresses U.S., European, and Japanese regulations

• Includes a chapter on herbal drug interactions

Compiling current information into one accessible resource, this is an excellent reference for industrial scientists and regulatory specialists in drug development as well as academic researchers and students in the fields of pharmacology, drug metabolism, and toxicology.

Aus dem Klappentext

Early evaluation of potential drug–drug interactions

Addressing the potential for adverse interactions among coadministered drugs before marketing a new drug can save time, money, and lives. In this reference, distinguished international experts comprehensively review the issues, relevant science, industrial practice, and regulatory agency positions on drug–drug interactions. Focusing on evaluation during the drug discovery process, Drug–Drug Interactions in Pharmaceutical Development:

• Details the major scientific concepts and preclinical experimental approaches

• Covers both clinical and nonclinical aspects

• Discusses in vitro and in vivo methodologies

• Covers genomic approaches

• Addresses U.S., European, and Japanese regulations

• Includes a chapter on herbal drug interactions

Compiling current information into one accessible resource, this is an excellent reference for industrial scientists and regulatory specialists in drug development as well as academic researchers and students in the fields of pharmacology, drug metabolism, and toxicology.